For decades, the story of psychedelic medicine in America was a story of obstacles. In 2026 that changed. In April, the White House signed an executive order telling federal agencies to move psychedelic treatments toward approval faster, and within a week the FDA put three psychedelic drug programs on a fast track. By early November, two applications were reportedly under FDA review and a third was days from filing.
The short answer to the question I hear most: no psychedelic drug is FDA approved yet. If the current reviews go well, the first psilocybin approval could come in 2027, and MDMA-assisted therapy for PTSD is back under review too.
I have followed this closely, partly because I worked on some of these trials (my disclosure is below). Here is what actually happened, and what it does and doesn't guarantee.
What did the April 2026 psychedelics executive order do?
Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," signed on April 18, 2026, tells federal agencies to prioritize psychedelic drugs. It does not approve, legalize or reschedule any drug. It does four main things:
FDA priority vouchers. The FDA Commissioner is to give National Priority Vouchers to psychedelic drugs that hold Breakthrough Therapy designation and meet the program's criteria. These vouchers target a final review of about one to two months, instead of the usual ten months or more.
Right to Try. The FDA and the DEA are to set up a pathway for eligible patients to access investigational psychedelics, including ibogaine, under the federal Right to Try Act.
Faster rescheduling. The Attorney General is to review any Schedule I product that completes Phase 3 trials for a serious mental health disorder, so that rescheduling can move quickly if the FDA approves it.
Money for states. HHS, through its research agency ARPA-H, is to put at least $50 million from existing funds toward partnerships with states that have psychedelic programs. Texas, which committed $50 million in state money to ibogaine trials that private partners must match, is the obvious first partner.
Legal scholars were quick to note the limits. A JAMA Viewpoint by I. Glenn Cohen and colleagues argued that the order mostly repackages authority the government already had. Mason Marks of Harvard's Petrie-Flom Center pointed out that the DEA is already required to act quickly on rescheduling after an approval. The order names only one psychedelic, ibogaine, twice, even though ibogaine carries known heart risks and has barely been studied in U.S. clinical trials. And it says nothing about religious or other non-medical use.
What the order mostly did was send a signal: the White House wants these drugs reviewed, and reviewed fast.
Which psychedelic drugs got FDA priority vouchers?
On April 24, 2026, the FDA awarded three vouchers to psychedelic programs: two for psilocybin in depression and one for methylone in PTSD.
Compass Pathways: psilocybin for treatment-resistant depression
Compass received a voucher and a rolling review for COMP360, its synthetic psilocybin, in treatment-resistant depression. It has two positive Phase 3 trials, and six-month data from the second one, released in July, showed a rapid and lasting effect. On November 3, Compass said it would file its final application within two weeks, and it is targeting a launch in the first half of 2027 if the FDA approves.
Usona Institute: psilocybin for major depressive disorder
Usona, a nonprofit, received a voucher for psilocybin in major depressive disorder, based on its Phase 3 trial, uAspire, of 238 adults. On November 2, Psychedelic Alpha reported that Usona had completed its new drug application; Usona declined to comment and the FDA has not confirmed it. When it received the voucher in April, Usona noted that it speeds the review but "does not alter scientific or regulatory standards."
Transcend Therapeutics: methylone for PTSD
The third voucher went to Transcend Therapeutics, which Otsuka agreed to buy in March, for methylone. Methylone is an empathogen chemically related to MDMA, studied for PTSD. It is the least advanced of the three programs.
The surprise was who didn't get a voucher: Resilient Pharmaceuticals, the company behind MDMA-assisted therapy for PTSD. Many in the field, including Psychedelic Alpha, had expected it to receive one.
Where does MDMA-assisted therapy stand with the FDA?
MDMA-assisted therapy for PTSD is under FDA review again, but without a voucher and without a public decision date. Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) has had a harder road than the psilocybin sponsors.
In June 2024, an FDA advisory committee voted 9 to 2 that the data did not show the treatment was effective, and 10 to 1 that its benefits did not outweigh its risks. In August 2024, the FDA declined to approve it and asked for a new trial addressing how long benefits last, how safety was measured, and how to reduce bias. The concerns centered on whether the data could be trusted: participants and therapists could usually tell who had received MDMA (called functional unblinding), and adverse events were not always recorded.
In August 2026, Resilient reportedly resubmitted the application without running a new Phase 3 trial, relying instead on an audit of its existing data. The resubmission came a month after the FDA finalized its guidance on psychedelic clinical trials. Supporters see it as a direct answer to the FDA's objections; skeptics see a bet that new analysis can stand in for new evidence. If the FDA treats it as a standard resubmission, its goal is to act within six months, which would point to early 2027.
So MDMA was filed first, but psilocybin, with two vouchers in hand, could well be decided first.
When could psilocybin or MDMA actually be approved?
The earliest realistic window for a first psilocybin approval is 2027; MDMA's timing is less certain. Three things could still change the picture:
The FDA can still say no. A voucher speeds the review; it doesn't lower the bar. And the agency has already rejected MDMA once.
Approval isn't access. An approved psilocybin or MDMA treatment would still need to be rescheduled by the DEA, delivered in certified settings with trained staff, and covered by insurers. Whether that looks like specialized clinics or something closer to ordinary prescribing will shape cost and who can actually get it.
First approvals shape trust. If fast reviews look rushed, the first drugs in this class pay the reputational price.
There is also the caution from the research side, which I covered in my post on psychedelics and pregnancy: for all the momentum at the FDA, whole populations, pregnant people among them, remain essentially unstudied. Post-marketing safety monitoring will have to fill those gaps.
What does this mean if you are looking for psychedelic therapy now?
For now, nothing changes in practice: psilocybin and MDMA remain Schedule I drugs, available legally only in clinical trials and, for psilocybin, state-regulated programs in Oregon and Colorado. Ketamine and esketamine are already legal, prescription options for some people with depression.
I walk through each route in Where Can I Get Psychedelic Therapy? Whatever route you take, preparation and integration matter, and that work doesn't have to wait for the FDA. You can read how I approach it on my psychedelic therapy page.
If you're in New York and weighing a clinical trial, ketamine treatment, or a psychedelic experience, preparation and integration therapy can help you approach it more safely and get more from it. I offer this by telehealth. Book a free 30-minute consultation.
My disclosure, and how I work with this
I was a site co-principal investigator and study therapist on Phase 2 and Phase 3 trials of MDMA-assisted therapy for PTSD sponsored by Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics), and a study therapist on COMPASS Pathways' Phase 2 trial of psilocybin therapy for treatment-resistant depression. I am Director of Clinical Implementation & Training at EPIC, the European Platform for Integration of MDMA in Mental Health Care, and a regulatory advisor to PsychedelicsEUROPE. I've tried to write this as plainly as I would want to read it.
I am Ingmar Gorman, PhD, a New York–licensed clinical psychologist offering psychedelic integration therapy and trauma therapy by telehealth to clients residing in New York State and clients living outside the USA, in English or Czech.
Frequently asked questions
Is psilocybin FDA approved?
No. As of November 2026, no psilocybin product is FDA approved. Applications from Compass Pathways and Usona Institute are complete or nearly complete, and both hold priority vouchers that target a one-to-two-month review. Even after approval, the DEA would need to reschedule psilocybin before it could be prescribed.
Is MDMA-assisted therapy FDA approved?
No. The FDA declined to approve it in August 2024. Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) reportedly resubmitted its application in August 2026 without a new Phase 3 trial, and no decision date has been made public.
Did the 2026 executive order legalize psychedelics?
No. Executive Order 14401 does not legalize, approve or reschedule any drug. It directs federal agencies to prioritize FDA review, set up a Right to Try pathway, prepare for faster rescheduling after approval, and fund partnerships with states.
What is an FDA National Priority Voucher?
It is an FDA pilot program that aims to shorten the final review of a drug application to about one to two months, instead of the standard ten months or more. It speeds up the review but does not change the evidence a drug needs for approval.
When could I get legal psilocybin therapy?
Today, outside clinical trials, Oregon and Colorado run state-regulated psilocybin programs. A federally approved psilocybin treatment could reach patients in 2027 at the earliest, if the FDA approves it and the DEA reschedules it, most likely through certified treatment centers.
Will insurance cover psychedelic therapy once it is approved?
No one knows yet. Coverage will depend on how insurers judge the evidence, the cost of the treatment and how it is delivered, and the executive order did not address it. FDA approval is the first step, not the last.
Can I see a psychedelic therapist in New York now?
Yes, for psychedelic integration therapy, which is legal talk therapy that helps you prepare for or make sense of a psychedelic experience. It does not involve providing psychedelics. I offer it by telehealth to clients residing in New York State and to clients living outside the USA.
Talk it through
If you're weighing psychedelic treatment, preparing for an experience, or making sense of one you've already had, I can help. I'm a New York–licensed clinical psychologist and served as a clinical trial investigator in psychedelic treatment research. I see clients by telehealth, in English or Czech. Book a free 30-minute consultation.
References
Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. April 18, 2026. 91 Fed. Reg. 21,709 (April 22, 2026). Text
U.S. Food and Drug Administration. FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. April 24, 2026. Link
Cohen IG, Lynch HF, McGuire AL. The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness. JAMA. 2026;336(5):367–368. doi:10.1001/jama.2026.11892. Link
Petrie-Flom Center, Harvard Law School. A New Executive Order on Psychedelics: Q&A with I. Glenn Cohen and Mason Marks. April 18, 2026. Link
Howard J, Tinker B. FDA moves to fast-track review of psilocybin and methylone for mental health. CNN, April 24, 2026. Link
Psychedelic Alpha. Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona. April 24, 2026. Link
Myshko D. FDA grants priority vouchers to 3 psychedelic medications. Managed Healthcare Executive, April 24, 2026. Link
Reuters. Trump signs order to accelerate access to psychedelic drug treatments. April 18, 2026. Link
Associated Press. Trump signs order to speed review of psychedelics, including the controversial drug ibogaine. April 18, 2026. Link
UTHealth Houston. UTHealth Houston, in collaboration with UTMB Health, awarded $50 million by the state of Texas to lead ibogaine clinical trials. EurekAlert. Link
Compass Pathways. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights. November 3, 2026. Link
Compass Pathways. Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile. July 2026. Link
Psychedelic Alpha. Usona Files Psilocybin for Depression NDA as Race With Compass Tightens. November 2, 2026. Link
ClinicalTrials.gov. Psilocybin for Major Depressive Disorder (uAspire), NCT06308653. Link
Psychedelic Alpha. Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application. August 12, 2026. Link
MAPS. MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA. August 10, 2026. Link
Drug Topics. FDA Advisory Panel Votes Against MDMA-Assisted Therapy for PTSD. July/August 2024. Link
U.S. Food and Drug Administration. MAPP 6020.4: Classifying Resubmissions in Response to Action Letters. Link
This post is a research and policy summary for public education. It is not medical or legal advice and is not a substitute for individual care.